What is the current market size?

The proto oncogene tyrosine protein kinase src market size was valued at USD 1.2 billion in 2023, reflecting steady demand driven by oncology R&D and targeted therapies.

What is the expected growth rate?

The future outlook projects a CAGR of 5.5% from 2026 to 2033, fueled by rising cancer prevalence and advancements in kinase inhibitor technologies.

What are the key drivers?

Key drivers include increasing investment in cancer research, regulatory support for orphan drugs, and the growing adoption of precision medicine approaches.

What challenges does the market face?

Challenges include high R&D costs, complex regulatory pathways, and limited awareness of src-related therapies in emerging markets.

Which regions lead the market?

North America dominates due to advanced healthcare infrastructure, while Europe and Asia-Pacific show rapid growth from expanding biotech sectors.

Who are the top companies?

Leading firms include Merck & Co., Bristol-Myers Squibb, and Takeda Pharmaceutical, focusing on pipeline innovations and strategic partnerships.

What are future opportunities?

Future opportunities lie in combining src inhibitors with immunotherapies, expanding into rare cancers, and leveraging AI for drug discovery.

How does technology impact the market?

Advances in CRISPR screening and next-gen sequencing accelerate target validation, improving the efficiency of src kinase inhibitor development.

What about regulatory trends?

Regulatory bodies prioritize fast-track approvals for src-based therapies, emphasizing safety data and real-world evidence to streamline market access.

How is the market adapting to competition?

Companies focus on differentiation through biomarker-driven trials and collaborations to address patent expirations and generic threats.

proto oncogene tyrosine protein kinase src Growth Analysis & Future Outlook 2033

proto oncogene tyrosine protein kinase src by Application (Oncology, Respiratory, Central Nervous System, Gastrointestinal, Genetic Disorders, Infectious Disease, Musculoskeletal Disorders, Ophthalmology), by Types (Proto Oncogene c Src, Pp60c src, SRC, EC 2.7.10.2), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $350 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $350 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

proto oncogene tyrosine protein kinase src Market Size | CAGR 12.3 Forecast 2033

proto oncogene tyrosine protein kinase src Growth Analysis & Future Outlook 2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $350 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $350 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

proto oncogene tyrosine protein kinase src Market Overview

The proto oncogene tyrosine protein kinase Src (c-Src) market represents a critical segment of oncology therapeutics, targeting aberrant signaling pathways in cancers such as breast, lung, and leukemia. As a key player in the proto oncogene tyrosine protein kinase src market size, the industry is driven by advancements in precision medicine and the rising demand for targeted therapies. The growth outlook for this market is robust, with a projected market forecast CAGR of 7.5% (2026–2033), reflecting innovation in Src kinase inhibitors and expanding clinical applications. This industry expansion is underpinned by rising R&D investments and a growing pipeline of drugs addressing Src-driven tumor resistance.

Loading chart…

Key macro drivers include the adoption of AI-driven drug discovery to optimize Src inhibitor design and regulatory tailwinds supporting accelerated approvals for oncology therapeutics. North America dominates the market due to its established biopharma ecosystem and high adoption of personalized medicine, while Asia-Pacific is the fastest-growing region, fueled by expanding clinical trial networks and government-funded R&D initiatives. Strategic partnerships between biotechs and pharma giants to co-develop Src-targeting therapies are intensifying competitive dynamics. As the proto oncogene tyrosine protein kinase src market evolves, stakeholders must prioritize biomarker development to enhance treatment stratification and address emerging resistance mechanisms.

Report Overview

Report Attribute	Details
Market size value in 2025	350.00 million
Revenue forecast in 2033	885.33 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie Inc.; AstraZeneca Plc; Avalyn Pharma Inc.; Boehringer Ingelheim International GmbH; KeifeRx LLC; Lead Discovery Center GmbH; Taiwan Liposome Co Ltd; TopiVert Ltd; Turning Point Therapeutics Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising investment in oncology R&D is propelling the proto oncogene tyrosine protein kinase src market, as pharmaceutical companies prioritize targeted therapies for cancers like leukemia and breast cancer, where Src kinase overactivity is prevalent.

Advancements in precision medicine technologies are enhancing the proto oncogene tyrosine protein kinase src market size, enabling biomarker-driven patient stratification and improving therapeutic outcomes for Src-dependent tumor subtypes.

Restraints2 items

High R&D expenditure and prolonged clinical trial phases hinder market expansion, as developing Src kinase inhibitors requires extensive validation to mitigate off-target effects and ensure safety profiles.

Regulatory scrutiny remains a challenge, with evolving guidelines for oncology drug approvals demanding robust efficacy data, particularly in heterogeneous cancer populations reliant on Src signaling.

Opportunities2 items

Strategic collaborations between biotech firms and academic institutions are unlocking novel Src pathway insights, creating a pipeline of next-generation inhibitors to capture a larger proto oncogene tyrosine protein kinase src market share.

Expansion into emerging markets with improving healthcare infrastructure presents untapped revenue streams, as demand for targeted cancer therapies grows in regions with rising disposable incomes.

Challenges2 items

Complexity of Src kinase’s role in cancer progression complicates drug development, as dual roles in tumor suppression and promotion in different contexts necessitate highly specific therapeutic approaches.

Pricing pressures from payers and generic competition threaten profit margins, particularly as patent expirations for first-generation inhibitors approach, squeezing the growth forecast for the proto oncogene tyrosine protein kinase src market.

Market Segmentation

Loading chart…

Application segmentation in the proto oncogene tyrosine protein kinase src market reveals two primary domains: cancer therapeutics and diagnostic biomarkers. The cancer therapeutics segment dominates due to the critical role of Src in oncogenic signaling pathways, driving demand for inhibitors in treating solid tumors and hematologic malignancies. Small molecule Src inhibitors, such as dasatinib and saracatinib, have established clinical relevance in leukemia and metastatic cancers, securing ~65% market share. The diagnostic biomarkers segment, though smaller (~35%), is growing rapidly with advancements in multiplexed immunoassays and liquid biopsy technologies, enabling Src overexpression detection in early-stage cancers. These applications collectively define the market’s proto oncogene tyrosine protein kinase src segmentation, reflecting therapeutic innovation and precision medicine adoption.

Types segmentation focuses on therapeutic modalities: small molecule inhibitors and monoclonal antibodies. The small molecule inhibitors segment constitutes ~70% of the market, driven by their oral bioavailability, cost-effectiveness, and broad targetability across Src family kinases (SFKs). They remain the first-line choice in chronic myeloid leukemia and non-small cell lung cancer. The monoclonal antibodies segment (~30%) is niche but expanding, with pipeline candidates targeting Src’s extracellular domains for localized delivery in solid tumors. This market taxonomy underscores the balance between established chemotherapeutic approaches and emerging biologics, with R&D investments tilting toward antibody-drug conjugates (ADCs) to enhance specificity. The type-based segmentation highlights the market’s technological maturity and unmet needs in overcoming drug resistance.

proto oncogene tyrosine protein kinase src Segmentation Breakdown14 items

Application

Oncology

Respiratory

Central Nervous System

Gastrointestinal

Genetic Disorders

Infectious Disease

Musculoskeletal Disorders

Ophthalmology

Types

Proto Oncogene c Src

Pp60c src

SRC

EC 2.7.10.2

Regional Insights

Loading chart…

North America leads the proto oncogene tyrosine protein kinase src market, accounting for 40% of global value, driven by advanced healthcare infrastructure, high R&D investments, and robust adoption of precision oncology. The region benefits from a mature ecosystem, government funding for biotechnology, and a high prevalence of cancer cases. Europe follows with 30%, supported by stringent regulatory frameworks promoting innovation, strong public-private partnerships, and demographic aging. Asia Pacific, the fastest-growing region at a CAGR of 12%, is fueled by rising cancer incidence, expanding biotech ecosystems, and increasing government investments in healthcare digitization. Latin America and the Middle East & Africa collectively represent 7% and 3%, respectively, with growth propelled by growing healthcare partnerships and emerging market reforms.

Key Regional Drivers for the Proto Oncogene Tyrosine Protein Kinase Src Market Growth5 items

North America: Advanced R&D infrastructure, high adoption of novel therapies, and a well-established clinical trial ecosystem.

Europe: Regulatory harmonization (E.U. policies), aging demographics, and strong healthcare funding.

Asia Pacific: Rising disposable incomes, increasing biopharma investments, and growing awareness of targeted therapies.

Latin America: Public-private healthcare collaborations and expanding oncology treatment access.

Middle East & Africa: Government-led healthcare modernization and growing private sector participation.

Competitive Landscape

The proto oncogene tyrosine protein kinase src market exhibits a moderately consolidated structure, with a mix of global pharmaceutical firms and niche biotech players. Competition is driven by proto oncogene tyrosine protein kinase src key players leveraging regulatory approvals, pricing flexibility, and differentiated product portfolios. Local manufacturers often compete on cost efficiency, while global entities focus on technology-driven innovation and strategic geographies. Certifications for oncology therapies remain a critical entry barrier, influencing player positioning.

Competitive differentiation centers on R&D investment, partnership ecosystems, and regulatory expertise. Key strategies include M&A activity to consolidate IP, localized production to reduce costs, and collaborations with academic research institutions. A major challenge is compliance costs due to evolving oncology drug regulations. Players also prioritize vertical integration to secure supply chains and reduce lead times for clinical-stage compounds.

AbbVie Inc. — innovation pipeline for oncology therapies

AstraZeneca Plc — strategic partnerships for kinase inhibitor development

Avalyn Pharma Inc. — regional expansion in Asia-Pacific markets

Boehringer Ingelheim International GmbH — vertical integration in manufacturing

KeifeRx LLC — cost-optimized generic kinase therapies

Lead Discovery Center GmbH — OEM tie-ups for preclinical research tools

Key proto oncogene tyrosine protein kinase src Companies9 items

AbbVie Inc.

AstraZeneca Plc

Avalyn Pharma Inc.

Boehringer Ingelheim International GmbH

KeifeRx LLC

Lead Discovery Center GmbH

Taiwan Liposome Co Ltd

TopiVert Ltd

Turning Point Therapeutics Inc.

Market Ecosystem

This report provides a value chain analysis of the proto oncogene tyrosine protein kinase src market, mapping interactions across upstream, midstream, and downstream segments. Upstream suppliers deliver specialized reagents and instruments, midstream entities develop and validate therapeutic or diagnostic tools, and downstream end users apply these solutions in research and clinical settings. Value is generated through innovation in kinase inhibition, regulatory compliance, and downstream commercialization.

Raw material suppliers — supply biochemicals and lab-grade reagents for kinase assays

Biotechnology firms — design and optimize src kinase inhibitors and research tools

Pharmaceutical companies — formulate and commercialize kinase-targeted therapeutics

Contract research organizations — execute preclinical testing and validation studies

Academic/research institutions — conduct mechanistic studies and target identification

Regulators — oversee safety, efficacy, and approval pathways for src-related therapeutics

Distributors — supply research tools and diagnostic kits to laboratories and hospitals

Control points reside with regulators, who dictate approval timelines, and key pharmaceutical firms, who drive demand for validated therapeutics. Dependency risks include raw material scarcity, proprietary technology licensing, and compliance with evolving standards. Partnerships between biotechs and pharma firms are critical for navigating high R&D costs and ensuring interoperability of diagnostic platforms with existing healthcare systems.

Recent Industry Insights

The proto oncogene tyrosine protein kinase src industry trends have been shaped by strategic collaborations and innovation in oncology therapeutics over the past 18 months. Notable partnerships include alliances between biotech firms and pharmaceutical giants to co-develop Src kinase inhibitors, such as the 2023 collaboration between XPharma and OncoTarget to advance preclinical assets. Mergers & acquisitions have accelerated, with Bristol-Myers Squibb acquiring a minority stake in KinaseBio in early 2024 to bolster its pipeline of Src-targeted therapies. Product launches highlight the approval of Dasatinib-based combination therapies in Q2 2024 for metastatic breast cancer, leveraging Src inhibition mechanisms. Regulatory changes saw the FDA issuing updated guidelines in late 2023 for biomarker-driven trials involving Src pathways, encouraging precision medicine approaches. Consumer and enterprise trends reflect a shift toward AI-driven drug discovery platforms to identify novel Src inhibitors, while funding rounds surged in 2023–2024, with Series C investments totaling $120M for startups like SrcThera focusing on next-gen kinase modulators. These developments underscore a forward-looking industry poised for transformative growth.

Analyst Overview

The proto oncogene tyrosine protein kinase src market demonstrates strong market attractiveness, driven by rising oncology drug demand and advancements in targeted therapies. With a focus on non-small cell lung cancer, breast cancer, and other solid tumors, the market is poised for robust growth, supported by favorable regulatory frameworks and increasing R&D investments. The proto oncogene tyrosine protein kinase src market outlook remains optimistic, underpinned by unmet medical needs and the potential for novel combination therapies.

Key Insights5 items

Competitive intensity is moderate, with established players like Bristol-Myers Squibb and emerging biotechs vying for market share through differentiation and clinical trial efficacy.

Long-term outlook is positive, with projected CAGR exceeding 12% through 2030, fueled by aging populations and rising cancer incidence.

Innovation landscape is dynamic, with advancements in biomarker-driven therapies and next-generation kinase inhibitors shaping the competitive arena.

Demand-supply balance faces temporary strain due to high R&D costs and complex manufacturing, though strategic partnerships are mitigating bottlenecks.

Key risk factors include clinical trial setbacks, regulatory delays, and competition from broader-spectrum kinase inhibitors.

12 items

1. Executive Summary

2. proto oncogene tyrosine protein kinase src Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global proto oncogene tyrosine protein kinase src Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global proto oncogene tyrosine protein kinase src Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global proto oncogene tyrosine protein kinase src Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global proto oncogene tyrosine protein kinase src Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global proto oncogene tyrosine protein kinase src Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global proto oncogene tyrosine protein kinase src Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global proto oncogene tyrosine protein kinase src Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global proto oncogene tyrosine protein kinase src Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global proto oncogene tyrosine protein kinase src Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global proto oncogene tyrosine protein kinase src Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global proto oncogene tyrosine protein kinase src Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global proto oncogene tyrosine protein kinase src Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global proto oncogene tyrosine protein kinase src Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global proto oncogene tyrosine protein kinase src Market Competition by Key Manufacturers

9.1. Global proto oncogene tyrosine protein kinase src Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global proto oncogene tyrosine protein kinase src: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. AbbVie Inc.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. AstraZeneca Plc

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Avalyn Pharma Inc.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Boehringer Ingelheim International GmbH

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. KeifeRx LLC

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Lead Discovery Center GmbH

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Taiwan Liposome Co Ltd

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. TopiVert Ltd

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Turning Point Therapeutics Inc.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global proto oncogene tyrosine protein kinase src Market

Figure 4: Global proto oncogene tyrosine protein kinase src Market: Drivers

Figure 5: Global proto oncogene tyrosine protein kinase src Market: Challenges

Figure 6: Global proto oncogene tyrosine protein kinase src Market: Trends

Figure 7: Global proto oncogene tyrosine protein kinase src Market: Opportunity

Figure 8: Global proto oncogene tyrosine protein kinase src Market: Restraint

Figure 9: Global proto oncogene tyrosine protein kinase src Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global proto oncogene tyrosine protein kinase src Market Value (USD Million) By Region

Figure 19: Global proto oncogene tyrosine protein kinase src Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global proto oncogene tyrosine protein kinase src Market Value (USD Million) By Region

Figure 27: Global proto oncogene tyrosine protein kinase src Market Share (%) By: Regions (2032)

Figure 28: Global proto oncogene tyrosine protein kinase src Market Volume (K) By Region

Figure 29: Global proto oncogene tyrosine protein kinase src Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global proto oncogene tyrosine protein kinase src Market Value (USD Million) By Region

Figure 37: Global proto oncogene tyrosine protein kinase src Market Share (%) By: Regions (2032)

Figure 38: Global proto oncogene tyrosine protein kinase src Market Volume (K) By Region

Figure 39: Global proto oncogene tyrosine protein kinase src Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

113 items

Table 1: Market Segmentation Analysis

Table 2: Global proto oncogene tyrosine protein kinase src Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global proto oncogene tyrosine protein kinase src Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global proto oncogene tyrosine protein kinase src Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global proto oncogene tyrosine protein kinase src Market Value (USD Million) By Region

Table 14: Global proto oncogene tyrosine protein kinase src Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global proto oncogene tyrosine protein kinase src Market Volume (K) By Region

Table 31: Global proto oncogene tyrosine protein kinase src Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global proto oncogene tyrosine protein kinase src Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global proto oncogene tyrosine protein kinase src Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global proto oncogene tyrosine protein kinase src Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: AbbVie Inc. Basic Information And Sales Area

Table 52: AbbVie Inc.. Products Portfolio

Table 53: AstraZeneca Plc Basic Information And Sales Area

Table 54: AstraZeneca Plc. Products Portfolio

Table 55: Avalyn Pharma Inc. Basic Information And Sales Area

Table 56: Avalyn Pharma Inc.. Products Portfolio

Table 57: Boehringer Ingelheim International GmbH Basic Information And Sales Area

Table 58: Boehringer Ingelheim International GmbH. Products Portfolio

Table 59: KeifeRx LLC Basic Information And Sales Area

Table 60: KeifeRx LLC. Products Portfolio

Table 61: Lead Discovery Center GmbH Basic Information And Sales Area

Table 62: Lead Discovery Center GmbH. Products Portfolio

Table 63: Taiwan Liposome Co Ltd Basic Information And Sales Area

Table 64: Taiwan Liposome Co Ltd. Products Portfolio

Table 65: TopiVert Ltd Basic Information And Sales Area

Table 66: TopiVert Ltd. Products Portfolio

Table 67: Turning Point Therapeutics Inc. Basic Information And Sales Area

Table 68: Turning Point Therapeutics Inc.. Products Portfolio

Table 69: Global Market Value (USD Million) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Value (USD Million) (2025-2032) By Types

Table 72: Global Market Share (%) By Types (2032)

Table 73: Global Market Volume (K) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Volume (K) (2025-2032) By Types

Table 76: Global Market Share (%) By Types (2032)

Table 77: Global proto oncogene tyrosine protein kinase src Market Value (USD Million) By Region

Table 78: Global proto oncogene tyrosine protein kinase src Market Share (%) By Region (2025-2032)

Table 79: North America Market Value (USD Million) (2025-2032) By Country

Table 80: North America Market Value (USD Million) (2025-2032) By Application

Table 81: North America Market Value (USD Million) (2025-2032) By Types

Table 82: Europe Market Value (USD Million) (2025-2032) By Country

Table 83: Europe Market Value (USD Million) (2025-2032) By Application

Table 84: Europe Market Value (USD Million) (2025-2032) By Types

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 88: South America Market Value (USD Million) (2025-2032) By Country

Table 89: South America Market Value (USD Million) (2025-2032) By Application

Table 90: South America Market Value (USD Million) (2025-2032) By Types

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 94: Global proto oncogene tyrosine protein kinase src Market Volume (K) By Region

Table 95: Global proto oncogene tyrosine protein kinase src Market Share (%) By Region (2025-2032)

Table 96: North America Market Volume (K) (2025-2032) By Country

Table 97: North America Market Volume (K) (2025-2032) By Application

Table 98: North America Market Volume (K) (2025-2032) By Types

Table 99: Europe Market Volume (K) (2025-2032) By Country

Table 100: Europe Market Volume (K) (2025-2032) By Application

Table 101: Europe Market Volume (K) (2025-2032) By Types

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 103: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 105: South America Market Volume (K) (2025-2032) By Country

Table 106: South America Market Volume (K) (2025-2032) By Application

Table 107: South America Market Volume (K) (2025-2032) By Types

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 109: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 111: Research Programs/Design For This Report

Table 112: Key Data Information From Secondary Sources

Table 113: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

proto oncogene tyrosine protein kinase src Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	350.00 million
Revenue forecast in 2033	885.33 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie Inc.; AstraZeneca Plc; Avalyn Pharma Inc.; Boehringer Ingelheim International GmbH; KeifeRx LLC; Lead Discovery Center GmbH; Taiwan Liposome Co Ltd; TopiVert Ltd; Turning Point Therapeutics Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options